Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT.

MLA

Kinoshita, Hannah, et al. “Outcome of Donor-Derived TAA-T Cell Therapy in Patients with High-Risk or Relapsed Acute Leukemia Post Allogeneic BMT.” Blood Advances, vol. 6, no. 8, Apr. 2022, pp. 2520–34. EBSCOhost, https://doi.org/10.1182/bloodadvances.2021006831.

APA

Kinoshita, H., Cooke, K. R., Grant, M., Stanojevic, M., Cruz, C. R., Keller, M., Fortiz, M. F., Hoq, F., Lang, H., Barrett, A. J., Liang, H., Tanna, J., Zhang, N., Shibli, A., Datar, A., Fulton, K., Kukadiya, D., Zhang, A., Williams, K. M., … Bollard, C. M. (2022). Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT. Blood Advances, 6(8), 2520–2534. https://doi.org/10.1182/bloodadvances.2021006831

Chicago

Kinoshita, Hannah, Kenneth R Cooke, Melanie Grant, Maja Stanojevic, C Russell Cruz, Michael Keller, Maria Fernanda Fortiz, et al. 2022. “Outcome of Donor-Derived TAA-T Cell Therapy in Patients with High-Risk or Relapsed Acute Leukemia Post Allogeneic BMT.” Blood Advances 6 (8): 2520–34. doi:10.1182/bloodadvances.2021006831.